TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28069399

Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 234

Group type: COMPARATOR
Intervention: No stoma
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study: 26008138

Group type: EXPERIMENTAL
Intervention: Intravenous doxycycline 200, 100 and 100mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous doxycycline 100, 50 and 50mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24094495

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of growth hormone (3mg/24h) for 60 hours
Number of subjects: 8
Study: 21724796

Group type: EXPERIMENTAL
Intervention: RENEW program (meal replacements twice daily, intensive instruction in nutrition and meal preparation, exercise, and goal setting for three months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 89
Study: 19792866

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy (ES/LC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Laparoscopic bile duct exploration (LBDE) during laparoscopic cholecystectomy (LC)
Number of subjects: 91
Study: 17072091

Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg kg(‐1))
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 55
Study: 12967076

Group type: EXPERIMENTAL
Intervention: One Coat Bond (a 'one-bottle' system)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One-Up Bond F (an 'all-in-one' system)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 60
Study: 10718946

Group type: EXPERIMENTAL
Intervention: rIFN (6 MU t.i.w.) plus ribavirin for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: rIFN (6 MU t.i.w.) without ribavirin for 6 months
Number of subjects: 60
Study: 8953321

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for bulimia nervosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral interventions and self-monitoring targeting body image
Number of subjects: 0
Study: 1411629

Group type: EXPERIMENTAL
Intervention: Carboplatin 60 mg/m2 with 67.2 Gy radiation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carboplatin 50 mg/m2 with 67.2 Gy radiation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy (various carboplatin doses with radiation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy (carboplatin/5-fluorouracil followed by conventional radiotherapy)
Number of subjects: 36
Study: 3899673

Group type: EXPERIMENTAL
Intervention: UCB JO28
Number of subjects: 20
Study: 29247149

Group type: EXPERIMENTAL
Intervention: TCZ‐SC 162 mg q2w
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo-SC q2w
Number of subjects: 656
Study: 27872513

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) administration 4 hours before amniocentesis
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no LF treatment)
Number of subjects: 111
Study: 24958689

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (SDR) bulk fill technique
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional 2 mm resin composite curing technique
Number of subjects: 38
Study: 22809012

Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 300 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 500 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pazufloxacin mesilate 1,000 mg
Number of subjects: 40
Study: 20484396

Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 351

Group type: COMPARATOR
Intervention: Endovascular repair
Number of subjects: 351
Study: 17583378

Group type: EXPERIMENTAL
Intervention: Chronic disease presence
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Acute symptoms upon arrival
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Risk factors for lacking medications
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Risk factors for presenting with acute symptoms
Number of subjects: 499
Study: 15821120

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 397

Group type: COMPARATOR
Intervention: Epirubicin 35 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 397
Study: 11863237

Group type: EXPERIMENTAL
Intervention: Imagery distraction
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: General distraction
Number of subjects: 41

Group type: COMPARATOR
Intervention: No instruction
Number of subjects: 41
Study: 9598837

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fat diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 17
Study: 7895227

Group type: EXPERIMENTAL
Intervention: Human CNP (10 pmol.kg‐1.min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II (6 ng.kg‐1.min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CNP
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2372338

Group type: EXPERIMENTAL
Intervention: Exercise on land at 70% VO2max
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise in water at 70% VO2max
Number of subjects: 7

Group type: COMPARATOR
Intervention: Comparison of land vs water exercise
Number of subjects: 7
Study: 480622

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 30
Study: 31436705

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplement provided to pregnant and lactating mothers and their children
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Microbiota maturity and diversity
Number of subjects: 631
Study: 28941189

Group type: EXPERIMENTAL
Intervention: Modified vocational rehabilitation approach delivered by trained occupational therapists and physical therapists (1.5-hour meeting, action plan, written materials, telephone calls at 3 weeks and 3 months)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group received written materials only
Number of subjects: 287
Study: 28798089

Group type: EXPERIMENTAL
Intervention: CPAP (n=151)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Conservative treatment (n=156)
Number of subjects: 307
Study: 25727121

Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 132

Group type: COMPARATOR
Intervention: Depression brochure
Number of subjects: 132
Study: 23924586

Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg once daily (OD) monotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: DRV/r 800/100 mg OD plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 30
Study: 20625394

Group type: EXPERIMENTAL
Intervention: Solar simulated radiation (SSR) at doses of 2 and 4 J/cm²
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vitro luciferase assay
Number of subjects: 20
Study: 19138933

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nondysplastic ACF
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Baseline SMAD4 expression in ACF
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ACF histological examination
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Immunohistochemical comparison of ACF with adjacent normal mucosa
Number of subjects: 45
Study: 16380297

Group type: EXPERIMENTAL
Intervention: Carbamazepine plus folic acid
Number of subjects: 82

Group type: COMPARATOR
Intervention: Carbamazepine alone
Number of subjects: 82
Study: 16594274

Group type: EXPERIMENTAL
Intervention: 8-week pilot intervention based on Social Cognitive Theory
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32
Study: 11189100

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (Cisplatin 100 mg/m2 on day 1 and fluorouracil 1000 mg/m2/day for 5 days, every 21 days) followed by loco-regional treatment.
Number of subjects: 318

Group type: COMPARATOR
Intervention: No chemotherapy followed by loco-regional treatment.
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (Cisplatin and fluorouracil) followed by loco-regional treatment.
Number of subjects: 318
Study: 9373888

Group type: EXPERIMENTAL
Intervention: estropipate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: estropipate + nor-ethindrone
Number of subjects: 38

Group type: COMPARATOR
Intervention: estrogen alone
Number of subjects: 38
Study: 7504379

Group type: EXPERIMENTAL
Intervention: Killed Mycobacterium leprae vaccine
Number of subjects: 147
Study: 2990332

Group type: EXPERIMENTAL
Intervention: Paper tissues treated with a combination of citric acid, malic acid, and sodium lauryl sulfate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo tissues containing sodium saccharin
Number of subjects: 18
Study: 31217024

Group type: EXPERIMENTAL
Intervention: Targeted radio advertising
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Television news coverage
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Mass mail-outs by a government health agency
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Recruitment promotions
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Mail-out by general practitioners (GPs)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Radio advertising
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Newspaper advertising
Number of subjects: 1007
Study: 30400977

Group type: EXPERIMENTAL
Intervention: Remifentanil combined with dexmedetomidine
Number of subjects: 354

Group type: COMPARATOR
Intervention: Antihypertensive drugs (urapidil, nicardipine, labetalol)
Number of subjects: 354
Study: 26528774

Group type: EXPERIMENTAL
Intervention: New Helmet (NH)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard Helmet (SH)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Endotracheal Tube
Number of subjects: 14
Study: 24460688

Group type: EXPERIMENTAL
Intervention: Infiltration with ICON and varnished with Duraphat (I+F)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sealed with Delton and varnished with Duraphat (S+F)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Only varnished with Duraphat (F)
Number of subjects: 50
Study: 22439868

Group type: EXPERIMENTAL
Intervention: SkinDoctor(®) fabric
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% cotton
Number of subjects: 12
Study: 20113961

Group type: EXPERIMENTAL
Intervention: Laser zona thinning
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (untreated zona pellucida)
Number of subjects: 400
Study: 18476430

Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection (SXTI) high dose (8 mL/d)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection (SXTI) low dose (6 mL/d)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 97
Study: 15546907

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid iv, administered as three monthly doses
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study: 12055562

Group type: EXPERIMENTAL
Intervention: Stentless bioprosthesis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stented bioprosthesis
Number of subjects: 28
Study: 10530684

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 3600 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7722692

Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 197

Group type: COMPARATOR
Intervention: Quarter of an orange (placebo)
Number of subjects: 197
Study: 3047380

Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sulindac 600 mg daily
Number of subjects: 162
Study: 31740860

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Facilitator-assisted learning
Number of subjects: 80
Study: 28124206

Group type: EXPERIMENTAL
Intervention: 0.2% NAC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2% NAC + 0.5% glycine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NAC
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5% glycine
Number of subjects: 120
Study: 26032168

Group type: EXPERIMENTAL
Intervention: Quinine (80 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxycodone (30 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quinine and Oxycodone (80 mg and 30 mg respectively)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 9
Study: 23530757

Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate regimen
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate regimen
Number of subjects: 300
Study: 20669228

Group type: EXPERIMENTAL
Intervention: Self-sampling kit
Number of subjects: 4160

Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 4160

Group type: EXPERIMENTAL
Intervention: Self-sampling kit and Reminder letter
Number of subjects: 4160
Study: 18458874

Group type: EXPERIMENTAL
Intervention: Open-circuit ventilators with plateau valve at helmet expiratory port
Number of subjects: 10

Group type: COMPARATOR
Intervention: Closed-circuit ventilator (helmet CPAP and pressure support ventilation)
Number of subjects: 10
Study: 22059194

Group type: EXPERIMENTAL
Intervention: Tapentadol IR (50 mg or 100 mg every 4 to 6 hours as needed)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Oxycodone IR (10 mg or 15 mg every 4 to 6 hours as needed)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 849

Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 849
Study: 16272183

Group type: EXPERIMENTAL
Intervention: Lorazepam 2mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11968154

Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (0.06, 0.12, 0.25, 0.5, 1.0, 2.0 mg/kg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (doses above 0.06 mg/kg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rhuMAb CD18
Number of subjects: 53
Study: 9893888

Group type: EXPERIMENTAL
Intervention: Evidence Based Emergency Medicine (EBEM) practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedures without proven scientific evidence
Number of subjects: 0
Study: 7923513

Group type: EXPERIMENTAL
Intervention: Lateral popliteal sciatic nerve block (group PS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcutaneous infiltration (group SC)
Number of subjects: 40
Study: 3072446

Group type: EXPERIMENTAL
Intervention: Anti-anginal therapy
Number of subjects: 0
Study: 12410124

Group type: EXPERIMENTAL
Intervention: Wide preperitoneal mesh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small onlay mesh prostheses
Number of subjects: 0
Study: 30159789

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (O3-FA)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 27494257

Group type: EXPERIMENTAL
Intervention: Voluntary finger extension (Fugl-Meyer Assessment hand sub item finger extension≥1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Return of voluntary finger extension
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Upper limb capacity
Number of subjects: 100
Study: 24510005

Group type: EXPERIMENTAL
Intervention: Brilliant Blue G (BBG) applied at 0.2 mL for 2 minutes under air conditions during ERM surgery
Number of subjects: 21
Study: 23422602

Group type: EXPERIMENTAL
Intervention: 0.05% Natrium‐Fluoride‐containing artificial saliva at pH 4 for three days
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% Natrium‐Fluoride‐containing artificial saliva at pH 4 for three days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% Natrium‐Fluoride‐containing artificial saliva at pH 6
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% Natrium‐Fluoride‐containing artificial saliva at pH 6
Number of subjects: 0
Study: 19081443

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Education Control
Number of subjects: 20
Study: 16202043

Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT) with infrared laser (780 nm, 30 mW, 10 s, 6.3 J/cm(2))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study: 12076869

Group type: EXPERIMENTAL
Intervention: 5 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Number of subjects: 298

Group type: COMPARATOR
Intervention: 3 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Number of subjects: 298
Study: 9988394

Group type: EXPERIMENTAL
Intervention: Fertilization antigen (FA)‐1
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control medium
Number of subjects: 18
Study: 7645613

Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 200

Group type: COMPARATOR
Intervention: Trial of labor
Number of subjects: 200
Study: 2141612

Group type: EXPERIMENTAL
Intervention: Captopril (average daily dose 269 mg, range 150 to 300)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Minoxidil (average daily dose 20 mg, range 7.5 to 30)
Number of subjects: 34
Study: 580588

Group type: EXPERIMENTAL
Intervention: meproscillarin
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31054907

Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 497

Group type: COMPARATOR
Intervention: Clinician-based sampling
Number of subjects: 497
Study: 28542003

Group type: EXPERIMENTAL
Intervention: Choice exercise condition
Number of subjects: 58

Group type: COMPARATOR
Intervention: No-choice exercise condition
Number of subjects: 58
Study: 25735993

Group type: EXPERIMENTAL
Intervention: MDMA (1.0 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MDMA (0.5 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No drug administration (Study 1)
Number of subjects: 32
Study: 23909121

Group type: EXPERIMENTAL
Intervention: N2O‐O2 mixture (Inspired O2 30%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air‐oxygen mixture (Inspired O2 50%)
Number of subjects: 30
Study: 21954280

Group type: COMPARATOR
Intervention: Oral contraceptive (OC) treatment
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: No oral contraceptive (non-OC) treatment
Number of subjects: 442
Study: 19184101

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 30
Study: 17143257

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy (paclitaxel plus carboplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with erlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other antiangiogenic approaches (small‐molecule tyrosine kinase inhibitors)
Number of subjects: 0
Study: 14656690

Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14 monoclonal antibody)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10782603

Group type: EXPERIMENTAL
Intervention: Out-of-hospital interventions
Number of subjects: 285
Study: 8997058

Group type: EXPERIMENTAL
Intervention: T‐X Block (n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gum bite block (n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: T‐X Block (n = 20)
Number of subjects: 200
Study: 1284161

Group type: EXPERIMENTAL
Intervention: GSR 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6741684

Group type: EXPERIMENTAL
Intervention: Treatment joiners
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-joiners
Number of subjects: 108
Study: 30216275

Group type: EXPERIMENTAL
Intervention: In situ simulation (ISS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mitigation strategies
Number of subjects: 73
Study: 30086780

Group type: EXPERIMENTAL
Intervention: Individualised exercise programme and behaviour change counselling (12-week duration, includes up to five in-person counselling sessions and written materials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care as recommended by evidence-based guidelines
Number of subjects: 0
Study: 26959690

Group type: EXPERIMENTAL
Intervention: Pascal® Photocoagulator (PP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional Argon Laser Photocoagulator (CALP)
Number of subjects: 80
Study: 24493633

Group type: EXPERIMENTAL
Intervention: Daily crossword intervention for 4 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (daily gratitude diary for 4 weeks)
Number of subjects: 37
Study: 22471295

Group type: EXPERIMENTAL
Intervention: SLCaps (soft gelatin capsules)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: HPCaps (hard gelatin capsules)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous vinflunine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both oral formulations (SLCaps and HPCaps)
Number of subjects: 34
Study: 21198252

Group type: EXPERIMENTAL
Intervention: One‐Day Training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Spaced Training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Full Mental Rotation Training, MRT and FLS
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MRT and FLS
Number of subjects: 62

Group type: COMPARATOR
Intervention: FLS‐only
Number of subjects: 62
Study: 17435527

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154